Low-grade serous carcinoma: molecular features and contemporary treatment strategies

References

• Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 2008;26(32):5284-93
   Google Scholar
• Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol 2002;20(5):1248-59
   PubMed Web of Science ®Google Scholar
• Malpica A, Deavers MT, Lu K, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 2004;28(4):496-504
   PubMed Web of Science ®Google Scholar
• Malpica A, Deavers MT, Tornos C, et al. Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma. Am J Surg Pathol 2007;31(8):1168-74
   PubMed Web of Science ®Google Scholar
• Gershenson DM. The life and times of low-grade serous carcinoma of the ovary. Am Soc Clin Oncol Educ Book 2013;10.1200/EdBook_AM.2013.33.e195
   PubMedGoogle Scholar
• Romero I, Sun CC, Wong KK, et al. Low-grade serous carcinoma: New concepts and emerging therapies. Gynecol Oncol 2013;130(3):660-6
   Google Scholar
• Gershenson DM, Sun CC, Lu KH, et al. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol 2006;108(2):361-8
   PubMed Web of Science ®Google Scholar
• Wong KK, Lu KH, Malpica A, et al. Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis. Int J Gynecol Pathol 2007;26(4):404-9
   PubMed Web of Science ®Google Scholar
• Singer G, Stohr R, Cope L, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: A mutational analysis with immunohistochemical correlation. Am J Surg Pathol 2005;29(2):218-24
   Google Scholar
• Farley J, Ozbun LL, Birrer MJ. Genomic analysis of epithelial ovarian cancer. Cell Res 2008;18(5):538-48
   Google Scholar
• Bodurka DC, Deavers MT, Tian C, et al. Reclassification of serous ovarian carcinoma by a 2-tier system: A gynecologic oncology group study. Cancer 2012;118(12):3087-94
   PubMed Web of Science ®Google Scholar
• Kurman RJ, Shih I. The origin and pathogenesis of epithelial ovarian cancer: A proposed unifying theory. Am J Surg Pathol 2010;34(3):433-43
   PubMed Web of Science ®Google Scholar
• Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68(3):700-10
   PubMed Web of Science ®Google Scholar
• Diaz-Padilla I, Malpica AL, Minig L, et al. Ovarian low-grade serous carcinoma: A comprehensive update. Gynecol Oncol 2012;126(2):279-85
   PubMed Web of Science ®Google Scholar
• Schmeler KM, Sun CC, Bodurka DC, et al. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 2008;108(3):510-14
   PubMed Web of Science ®Google Scholar
• Crispens MA, Bodurka D, Deavers M, et al. Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet Gynecol 2002;99(1):3-10
   PubMed Web of Science ®Google Scholar
• Fader AN, Java J, Ueda S, et al. Survival in women with grade 1 serous ovarian carcinoma. Obstet Gynecol 2013;122(2 Pt 1):225-32
   PubMed Web of Science ®Google Scholar
• Gershenson DM, Sun CC, Iyer RB, et al. Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 2012;125(3):661-6
   PubMed Web of Science ®Google Scholar
• Crane EK, Sun CC, Ramirez PT, et al. The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer. Gynecol Oncol 2015;136(1):25-9
   PubMed Web of Science ®Google Scholar
• Gershenson DM, Sun CC, Bodurka D, et al. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol 2009;114(1):48-52
   PubMed Web of Science ®Google Scholar
• Shimizu Y, Kamoi S, Amada S, et al. Toward the development of a universal grading system for ovarian epithelial carcinoma. I. prognostic significance of histopathologic features–problems involved in the architectural grading system. Gynecol Oncol 1998;70(1):2-12
   PubMed Web of Science ®Google Scholar
• Classification and staging of malignant tumours in the female pelvis. Acta Obstet Gynecol Scand 1971;50(1):1-7
   PubMed Web of Science ®Google Scholar
• Chen C, Li J, Yao G, et al. Tubal origin of ovarian low-grade serous carcinoma. Am J Clin Exp Obstet Gynecol 2013;1(1):13-36
   Google Scholar
• Li J, Abushahin N, Pang S, et al. Tubal origin of ’ovarian’ low-grade serous carcinoma. Mod Pathol 2011;24(11):1488-99
   Google Scholar
• Singer G, Oldt RIII, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003;95(6):484-6
   PubMed Web of Science ®Google Scholar
• O’Neill CJ, Deavers MT, Malpica A, et al. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: Significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. Am J Surg Pathol 2005;29(8):1034-41
   Google Scholar
• Groen RS, Gershenson DM, Fader AN. Updates and emerging therapies for rare epithelial ovarian cancers: One size no longer fits all. Gynecol Oncol 2015;136(2):373-83
   PubMed Web of Science ®Google Scholar
• King ER, Zu Z, Tsang YT, et al. The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma. Gynecol Oncol 2011;123(1):13-18
   Google Scholar
• Seidman JD, Horkayne-Szakaly I, Cosin JA, et al. Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum. Gynecol Oncol 2006;103(2):703-8
   Google Scholar
• Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarian
   Google Scholar
• Bristow RE, Gossett DR, Shook DR, et al. Micropapillary serous ovarian carcinoma: Surgical management and clinical outcome. Gynecol Oncol 2002;86(2):163-70
   Google Scholar
• Dizon DS, Dupont J, Anderson S, et al. Treatment of recurrent ovarian cancer: A retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. the memorial sloan-kettering cancer center experience. Gynecol Oncol 2003;91(3):584-90
   PubMed Web of Science ®Google Scholar
• Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361(9375):2099-106
   PubMed Web of Science ®Google Scholar
• Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: A randomized Phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19(14):3312-22
   PubMed Web of Science ®Google Scholar
• Hou JY, Kelly MG, Yu H, et al. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. Gynecol Oncol 2007;105(1):211-17
   PubMed Web of Science ®Google Scholar
• Bristow RE, Gossett DR, Shook DR, et al. Recurrent micropapillary serous ovarian carcinoma. Cancer 2002;95(4):791-800
   PubMed Web of Science ®Google Scholar
• D’Agostino G, Amant F, Berteloot P, et al. Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer. Gynecol Oncol 2003;88(3):266-9
   PubMed Web of Science ®Google Scholar
• Gourley C, Farley J, Provencher DM, et al. Gynecologic cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas. Int J Gynecol Cancer 2014;24(9 Suppl 3):S9-13
   PubMed Web of Science ®Google Scholar
• Santillan A, Kim YW, Zahurak ML, et al. Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma. Int J Gynecol Cancer 2007;17(3):601-6
   Google Scholar
• Smyth JF, Gourley C, Walker G, et al. Antiestrogen therapy is active in selected ovarian cancer cases: The use of letrozole in estrogen receptor-positive patients. Clin Cancer Res 2007;13(12):3617-22
   PubMed Web of Science ®Google Scholar
• Zhang N, Moran MS, Huo Q, et al. The hormonal receptor status in breast cancer can be altered by neoadjuvant chemotherapy: A meta-analysis. Cancer Invest 2011;29(9):594-8
   PubMed Web of Science ®Google Scholar
• Grisham RN, Iyer G, Sala E, et al. Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer. Int J Gynecol Cancer 2014;24(6):1010-14
   PubMed Web of Science ®Google Scholar
• Farley J, Brady WE, Vathipadiekal V, et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: An open-label, single-arm, Phase 2 study. Lancet Oncol 2013;14(2):134-40
   PubMed Web of Science ®Google Scholar
• Dry JR, Pavey S, Pratilas CA, et al. Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res 2010;70(6):2264-73
   PubMed Web of Science ®Google Scholar
• Available from: http://www.clinicaltrials.gov
   Google Scholar